OBJECTIVE AND DESIGN: Genetic polymorphisms of chemokines and their receptors were reported to be independent risk factors for inflammation associated disease. We explored the role of CCR5-Δ32, CCR5-G59029A, CX3CR1 V249I and T280M gene polymorphisms as susceptibility for end stage renal disease (ESRD). SUBJECTS AND METHODS: We genotyped 258 ESRD and 569 healthy controls by sequence-specific primers and RFLP and examined their association. RESULTS: There was significant difference in genotype frequencies of CCR5-G59029A (p = 0.005), and CX3CR1 V249I (p < 0.0001) between ESRD and controls. No homozygous individuals were observed for CCR5-Δ32. The haplotype analysis of all four studied genes reveled that haplotype +/A/T/I was more significant in patients and associated with higher risk (OR = 2.95) of ESRD. Further, the haplotype of CX3CR1 (T280M, V249I) gene showed 3.6-fold higher in an individual carrying T/I haplotype. No risk was seen for CCR5 haplotypes. CONCLUSIONS: These results highlight the role of CCR5 and CX3CR1 in ESRD.
OBJECTIVE AND DESIGN: Genetic polymorphisms of chemokines and their receptors were reported to be independent risk factors for inflammation associated disease. We explored the role of CCR5-Δ32, CCR5-G59029A, CX3CR1V249I and T280M gene polymorphisms as susceptibility for end stage renal disease (ESRD). SUBJECTS AND METHODS: We genotyped 258 ESRD and 569 healthy controls by sequence-specific primers and RFLP and examined their association. RESULTS: There was significant difference in genotype frequencies of CCR5-G59029A (p = 0.005), and CX3CR1V249I (p < 0.0001) between ESRD and controls. No homozygous individuals were observed for CCR5-Δ32. The haplotype analysis of all four studied genes reveled that haplotype +/A/T/I was more significant in patients and associated with higher risk (OR = 2.95) of ESRD. Further, the haplotype of CX3CR1 (T280M, V249I) gene showed 3.6-fold higher in an individual carrying T/I haplotype. No risk was seen for CCR5 haplotypes. CONCLUSIONS: These results highlight the role of CCR5 and CX3CR1 in ESRD.
Authors: Bernd Schröppel; Michael Fischereder; Marvin Lin; Brad Marder; Tom Schiano; Bernhard K Krämer; Barbara Murphy Journal: J Clin Immunol Date: 2002-11 Impact factor: 8.317
Authors: Eleonora Simeoni; Giuseppe Vassalli; Charles Seydoux; David Ramsay; Georg Noll; Ludwig K von Segesser; Sylvain Fleury Journal: Transplantation Date: 2005-11-15 Impact factor: 4.939
Authors: Fan Wang; Mei Hong Xiu; Dong Feng Zhou; Lian Yuan Cao; Gui Ying Wu; Therese A Kosten; Thomas R Kosten; Xiang Yang Zhang Journal: Schizophr Res Date: 2008-03-04 Impact factor: 4.939
Authors: Anurag Rathore; Animesh Chatterjee; P Sivarama; Naohiko Yamamoto; Pradeep K Singhal; Tapan N Dhole Journal: AIDS Res Hum Retroviruses Date: 2009-11 Impact factor: 2.205
Authors: S Faure; L Meyer; D Costagliola; C Vaneensberghe; E Genin; B Autran; J F Delfraissy; D H McDermott; P M Murphy; P Debré; I Théodorou; C Combadière Journal: Science Date: 2000-03-24 Impact factor: 47.728
Authors: Friso L H Muntinghe; Marion Verduijn; Mike W Zuurman; Diana C Grootendorst; Juan Jesus Carrero; Abdul Rashid Qureshi; Karin Luttropp; Louise Nordfors; Bengt Lindholm; Vincent Brandenburg; Martin Schalling; Peter Stenvinkel; Elisabeth W Boeschoten; Raymond T Krediet; Gerjan Navis; Friedo W Dekker Journal: J Am Soc Nephrol Date: 2009-04-23 Impact factor: 10.121
Authors: Chloe L Thio; Jacquie Astemborski; Rasmi Thomas; Timothy Mosbruger; Mallory D Witt; James J Goedert; Keith Hoots; Cherie Winkler; David L Thomas; Mary Carrington Journal: J Immunol Date: 2008-12-01 Impact factor: 5.422
Authors: Łukasz Woźny; Joanna Żywiec; Katarzyna Gosek; Roman Kuźniewicz; Sylwia Górczyńska-Kosiorz; Wanda Trautsolt; Mirosław Śnit; Władysław Grzeszczak Journal: Int J Environ Res Public Health Date: 2021-02-23 Impact factor: 3.390
Authors: Asmaa Fathelbab Ibrahim; Asmaa Osama Bakr Seddik Osman; Lamiaa M Elabbasy; Mostafa Abdelsalam; A M Wahab; Maysaa El Sayed Zaki; Radwa Ahmed Rabea Abdel-Latif Journal: Int J Nephrol Date: 2021-04-24